Почетна › Мијелодиспластични синдроми › Тексас › Houston
Kliničke studije za Мијелодиспластични синдроми u gradu Houston, TX
43 studija za Мијелодиспластични синдроми traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Тражи се учесникФаза 3
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
- LUMI Research, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Тражи се учесникФаза 3
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Personalized NK Cell Therapy in CBT
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Тражи се учесникФаза 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Тражи се учесникФаза 1/2
- MD Anderson, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Тражи се учесникФаза 1/2
- Research Site, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Тражи се учесникФаза 1/2
- MD Anderson, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Тражи се учесникФаза 2
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Тражи се учесникФаза 1Здраве особе су добродошле
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Тражи се учесникФаза 2/3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Тражи се учесникФаза 1/2
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
Тражи се учесникФаза 1/2
- Md Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Тражи се учесникФаза 2Здраве особе су добродошле
- MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Тражи се учесникФаза 1/2
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Тражи се учесникФаза 3
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Тражи се учесникФаза 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Тражи се учесникФаза 2/3Здраве особе су добродошле
- M D Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Тражи се учесникФаза 1/2
- M D Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Тражи се учесникФаза 2
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Тражи се учесникФаза 2
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Тражи се учесникФаза 1
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Тражи се учесникФаза 1
- MD Anderson, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Тражи се учесникФаза 1/2
- MDACC, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Тражи се учесникФаза 1
- The University of Texas M.D. Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Studije za Мијелодиспластични синдроми u drugim gradovima
- Baldwin Park, CA27 студија
- New York City, NY22 студија
- Seattle, WA21 студија
- Boston, MA20 студија
- Tampa, FL20 студија
- Washington, DC19 студија
- Miami, FL17 студија
- Durham, NC14 студија
- Columbus, OH14 студија
- Atlanta, GA13 студија
- Chicago, IL13 студија
- St. Louis, MO13 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Рак јајника90 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.